lepusutide acetate

Lepusutide acetate (JY-034) is a synthetic peptide and a selective guanylate cyclase-C (GC-C) agonist developed by Shenzhen Jianyuan Pharmaceutical Technology. It is primarily being investigated for the treatment of ulcerative colitis. By binding to and activating GC-C receptors on the apical membrane of the intestinal epithelium, lepusutide acetate triggers an increase in intracellular and extracellular cyclic guanosine monophosphate (cGMP). This signaling pathway regulates ion transport, increases fluid secretion into the intestinal lumen, and is thought to exert anti-inflammatory effects and improve intestinal barrier function. The drug is designed to act locally within the gastrointestinal tract with minimal systemic absorption, potentially offering a favorable safety profile for patients with inflammatory bowel disease.

Other names

lepusutide